AstraZeneca CEO Pascal Soriot (File photo, AP)

In an end-of-year sur­prise, As­traZeneca nabs rare dis­ease stal­wart Alex­ion in $39B buy­out. But why?

Af­ter spend­ing the past 8 years script­ing a turn­around that would make As­traZeneca $AZN a re­li­able growth sto­ry and glob­al per­former in on­col­o­gy, CEO Pas­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.